scholarly journals Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour

2020 ◽  
Vol 31 (1) ◽  
pp. 80-84 ◽  
Author(s):  
Sara Elena Rebuzzi ◽  
Massimiliano Grassi ◽  
Fabio Catalano ◽  
Michele Buscaglia ◽  
Rossella Bertulli ◽  
...  
Keyword(s):  
Giant Cell ◽  
Systemic Treatment ◽  
Giant Cell Tumour ◽  
Treatment Options ◽  
Cell Tumour ◽  
Tenosynovial Giant Cell Tumour

Management of tenosynovial giant cell tumour of the foot and ankle

2021 ◽  
Vol 103-B (4) ◽  
pp. 788-794
Author(s):  
Geert Spierenburg ◽  
Sarah Tamar Lancaster ◽  
Lizz van der Heijden ◽  
Monique J. L. Mastboom ◽  
Hans Gelderblom ◽  
...  
Keyword(s):  
Side Effects ◽  
Giant Cell ◽  
Systemic Treatment ◽  
Giant Cell Tumour ◽  
Arthroscopic Surgery ◽  
Primary Treatment ◽  
Cell Tumour ◽  
Foot And Ankle ◽  
Tenosynovial Giant Cell Tumour

Aims Tenosynovial giant cell tumour (TGCT) is one of the most common soft-tissue tumours of the foot and ankle and can behave in a locally aggressive manner. Tumour control can be difficult, despite the various methods of treatment available. Since treatment guidelines are lacking, the aim of this study was to review the multidisciplinary management by presenting the largest series of TGCT of the foot and ankle to date from two specialized sarcoma centres. Methods The Oxford Tumour Registry and the Leiden University Medical Centre Sarcoma Registry were retrospectively reviewed for patients with histologically proven foot and ankle TGCT diagnosed between January 2002 and August 2019. Results A total of 84 patients were included. There were 39 men and 45 women with a mean age at primary treatment of 38.3 years (9 to 72). The median follow-up was 46.5 months (interquartile range (IQR) 21.3 to 82.3). Localized-type TGCT (n = 15) predominantly affected forefoot, whereas diffuse-type TGCT (Dt-TGCT) (n = 9) tended to panarticular involvement. TGCT was not included in the radiological differential diagnosis in 20% (n = 15/75). Most patients had open rather than arthroscopic surgery (76 vs 17). The highest recurrence rates were seen with Dt-TGCT (61%; n = 23/38), panarticular involvement (83%; n = 5/8), and after arthroscopy (47%; n = 8/17). Three (4%) fusions were carried out for osteochondral destruction by Dt-TGCT. There were 14 (16%) patients with Dt-TGCT who underwent systemic treatment, mostly in refractory cases (79%; n = 11). TGCT initially decreased or stabilized in 12 patients (86%), but progressed in five (36%) during follow-up; all five underwent subsequent surgery. Side effects were reported in 12 patients (86%). Conclusion We recommend open surgical excision as the primary treatment for TGCT of the foot and ankle, particularly in patients with Dt-TGCT with extra-articular involvement. Severe osteochondral destruction may justify salvage procedures, although these are not often undertaken. Systemic treatment is indicated for unresectable or refractory cases. However, side effects are commonly experienced, and relapses may occur once treatment has ceased. Cite this article: Bone Joint J 2021;103-B(4):788–794.

scholarly journals RECURRENT GIANT CELL TUMOUR OF THE FLEXOR TENDON SHEATH OF THE DISTAL PALM – A CASE REPORT

2020 ◽  
pp. 1-2
Author(s):  
Surya Rao Rao Venkata Mahipathy ◽  
Alagar Raja Durairaj ◽  
Narayanamurthy Sundaramurthy ◽  
Anand Prasath Jayachandiran ◽  
Volga Harikrishnan
Keyword(s):  
Giant Cell ◽  
Giant Cell Tumour ◽  
Flexor Tendon ◽  
Imaging Modality ◽  
Benign Lesion ◽  
Tendon Sheath ◽  
Cell Tumour ◽  
Recurrence Rates ◽  
Flexor Tendon Sheath ◽  
Tenosynovial Giant Cell Tumour

Giant cell tumor of the tendon sheath is a common benign lesion of the hand. They are also known as tenosynovial giant cell tumours. Magnetic resonance imaging is the imaging modality of choice and the current treatment is surgical excision of the lesion. This lesion is particularly known for its high recurrence rates. Here, we present a case of a recurrent tenosynovial giant cell tumour of the flexor tendon sheath of the index finger at the distal palmar crease. Diagnosis was confirmed by MRI and the lesion was excised. Histopathology revealed a localized type of tenosynovial giant cell tumour.

An unusual presentation of diffuse tenosynovial giant cell tumour in the neck

2003 ◽  
Vol 43 (4) ◽  
pp. 393-396 ◽  
Author(s):  
G Pillai ◽  
M Nicolas ◽  
K Lwin ◽  
F Pezzella ◽  
K Gatter
Keyword(s):  
Giant Cell ◽  
Giant Cell Tumour ◽  
Cell Tumour ◽  
Unusual Presentation ◽  
Tenosynovial Giant Cell Tumour

Radiological Assessment of Giant Cell Tumour of Bone in the Sacrum: From Diagnosis to Treatment Response Evaluation

2021 ◽  
Vol 17 ◽  
Author(s):  
Kirsten Van Langevelde ◽  
Niels Van Vucht ◽  
Shinji Tsukamoto ◽  
Andreas F. Mavrogenis ◽  
Costantino Errani
Keyword(s):  
Soft Tissue ◽  
Giant Cell ◽  
Giant Cell Tumour ◽  
Imaging Modality ◽  
Treatment Options ◽  
World Health Organisation ◽  
Axial Skeleton ◽  
Cell Tumour ◽  
World Health ◽  
Response Evaluation

: Giant cell tumour of bone (GCTB) typically occurs in young adults from 20-40 years old. Although the majority of lesions are located in the epi-metaphyses of the long bones, approximately one third of tumours is located in the axial skeleton, of which only 4% in the sacrum. Sacral tumours tend to be large at the time of presentation, and they present with aggressive features such as marked cortical destruction and an associated soft tissue component. The 2020 World Health Organisation classification of Soft Tissue and Bone Tumours describes GCTB as neoplasm which is locally aggressive and rarely metastasizing. The tumour contains three different cell types: neoplastic mononuclear stromal cells, macrophages and osteoclast-like giant cells. Two tumour subtypes were defined: conventional GCTB and malignant GCTB. Only 1-4% of GCTB is malignant. In this review article, we will discuss imaging findings at the time of diagnosis to guide the musculoskeletal radiologist in reporting these tumours. In addition, imaging for response evaluation after various treatment options will be addressed, such as surgery, radiotherapy, embolization and denosumab. Specific findings will be presented per imaging modality and illustrated by cases from our tertiary sarcoma referral center. Common postoperative and post radiotherapy findings in GCTB of the sacrum on MRI will be discussed.

Treatment of tenosynovial giant-cell tumour types

2019 ◽  
Vol 20 (8) ◽  
pp. e399
Author(s):  
Yoshihiro Nishida ◽  
Kunihiro Ikuta
Keyword(s):  
Giant Cell ◽  
Giant Cell Tumour ◽  
Cell Tumour ◽  
Tenosynovial Giant Cell Tumour
Sign in / Sign up

Export Citation Format

Share Document